I certainly don't know this is the case, but others don't
I certainly don't know this is the case, but others don't know it isn't. Let's suppose OWCP had a discussion with one or more other companies where it was agreed that under confidentiality, they would say nothing about the progress of trials currently underway until they are completed. Under such an arrangement, they couldn't tell us of expansion of the trial, nor could they say it was fully enrolled, or that the target date was being revised. In short, whether we liked it or not, OWCP may have agreed to muzzle themselves until results were finalized and could be shared with both investors and potential partners.
If this were the case, it would suggest a reason why nothing more could be said in either the quarterly, or the recent letter. It would also explain why OWCP hasn't been at any of the recent cannabis conferences held in various parts of the world.
If I'm right about this, if the trial results are as positive as most here believe they will be, growth in the stock could be truly explosive as not only would we get positive trial results, but shortly thereafter one or more partnerships would be announced because the potential partner wanted to see results before finalizing a partnership. I would believe in this case the potential partner would pay substantially more to wait for results, but in doing so their risk of failure would be greatly reduced as efficacy would be shown before they invested.
I'm not saying this is the case, just a possibility, but I don't know of any better way to explain the company's unwillingness to discuss the status of one or more ongoing trials.
Gary
4
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Big Moves in the Tech Jungle: FiEE's Comeback Let's chew the fat on FiEE, Inc., a company that's left its hardware-heavy past in the dust and grabbed the bull by the horns with fresh, AI-driven brand tech solutions. We're talking a whopping 382.1% revenue increase. Now, that's not chump change. From barely scraping $2 million last year to raking in $9.6 million just for...
Continue Reading
Crafting Stories That Endure You ever notice how some things just fade away after the holidays? Schools don't want their donor stories to go out like last year's tinsel. Rocket Alumni Solutions strikes right at the core of this concern. They recommend crafting donor recognition that lasts beyond GivingTuesday, by anchoring the story in the school's community. This isn't...
Continue Reading
Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...
Continue Reading
Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...
Continue Reading
A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...
Continue Reading
A New Chapter in Antibody Discovery Well, color me intrigued. Biointron, a name you'd recognize if you've got even a toe in the biotech pond, just threw a serious curveball into the antibody discovery game with RushDATA™—an AI- and machine learning-driven platform that's packing a punch. And it's not just about throwing tech buzzwords around; this thing clocks...
Continue Reading
BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...
Continue Reading
Cardinal Infrastructure Group Under Intense Investor Scrutiny Well, ain't this a messy soup of financial blunders? Cardinal Infrastructure Group (Nasdaq: CDNL) finds itself on the sharp end of a potential securities law investigation, thanks to some colossal screw-ups in managing project costs and estimates. Investors are rightly pissed after the company's shares...
Continue Reading
KeyCorp Drops a Major Redemption Bombshell Out of the blue, KeyCorp (NYSE: KEY) just tossed a curveball at investors with the announcement they’re redeeming every last one of their Series E Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock shares come December 15, 2026. This move is bound to stir the pot a bit even if you’ve been around the block a few...
Continue Reading
A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...
Continue Reading
Top 5 Most Recently Viewed Articles
Investors Targeting Crocs Encouraged to Join Class Action Faruqi & Faruqi, LLP, a prominent name in securities litigation, is reaching out to investors who have experienced significant losses in Crocs stock to participate in an emerging federal class action lawsuit. The firm is particularly concerned with those who incurred losses exceeding $50,000. The deadline to assume...
Continue Reading
Chaoyang: A Tapestry of Global Life Taking a stroll through Beijing's Chaoyang district, you'd catch more than just a glimpse of its soaring skyscrapers or riverside parks—you're stepping into a melting pot of cultures and modern business ethos. It’s not puffery when they say this district marries the world’s diversified cultures with dynamic business environments;...
Continue Reading
Foot Locker on the Path to Recovery Recent analysis by Needham's analyst Tom Nikic illustrates a promising outlook for Foot Locker, Inc. (NYSE: FL), highlighting how the company is positioned for earnings recovery in the coming year. The strengthened partnership with Nike, along with growth in non-Nike brands, and recent investments in selling, general and administrative...
Continue Reading
The Rising Trend of Milking Automation Market The milking automation market is currently experiencing a significant transformation, with estimates projecting a growth to USD 3.68 billion by 2030. This steady rise reflects a robust CAGR of 7.1% from an initial valuation of USD 2.61 billion. Factors driving this expansion include increasing demand for milk, labor shortages...
Continue Reading
Immatics Updates on ACTengine® IMA203 for Melanoma Patients Overview: Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company specializing in the development of T cell-redirecting immunotherapies, has recently announced significant advancements in its clinical trial of ACTengine® IMA203. The focus of this update is on the therapy's application in...
Continue Reading